anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A tetracycline calcium chloride complex is prepared by reacting tetracycline in solution below pH 2.5 with calcium chloride to form a solution which is then adjusted to pH 3.0 to 6.0, and preferably 3.0 to 4.0, by means of a base such as ammonium hydroxide or sodium hydroxide, and collecting the precipitated complex.  The tetracycline may be in the form of the anhydrous or crystalline base or an acid addition salt, e.g. the hydrochloride or sulphate, and is adjusted to the desired pH by means of a strong mineral acid such as hydrochloric or sulphuric acid.  The reaction solvent is preferably water but may be a water miscible alcohol or ketone or an aqueous solution thereof. The preferred complex contains 4 molecules of tetracycline to 1 mol. calcium chloride.  The complex is stable in aqueous suspension and is used medicinally (see Group VI).  Reference has been directed by the Comptroller to Specification 747,779.ALSO:A tetracycline calcium chloride complex (see Group IV(b)) is employed in therapeutic preparations alone or in combination with other therapeutically active substances.  Such preparations may be aqueous or oily suspensions, powders, tablets, troches, lozenges or capsules. Optional additions are buffers e.g. sodium citrate, preservatives e.g. phenol, suspending and dispersing agents e.g. methyl cellulose, binders such as gum tragacanth, diluents, lubricants, masticatory substances and stabilizing agents.  The tetracycline calcium chloride may be coated with one or more suspending agents such as lecithin. The complex may be comminuted to any desired particle size. Specified therapeutically active substances are (a) antihistamines (b) sulpha drugs e.g. sulphadiazine (c) vitamins e.g. vitamin A (d) lipstropic agents (e) stimulants e.g. caffine (f) analgesics e.g. asprin (g) laxatives e.g. phenol phthalein (h) sedatives e.g. barbiturates (i) other antibiotics e.g. penicillin, streptomycin, dihydrostreptomycin, neomycin, bacitracin, polymixin, tyrothricin, erythromycin, aureomycin, oxytetracycline, chloramphenicol and magramycin (j) spreading agents e.g. hyaluronidase and (k) hormones e.g. cortisone. Multiple combinations of the above active materials may be used e.g. sulphadiazine and sulphamerazine.  Injections of the complex in peanut oil may be gelled with aluminium monostearate. Reference has been directed by the Comptroller to Specification 747,779.
PURPOSE:To enable efficient obtaining of a novel polypeptide in high purity by substituting gamma-carboxyglutamic acid (Gla) in human osteocalcin(OC) with glutamic acid(Glu). CONSTITUTION:Amino acids are sequenced and contained to provide a polypeptide (A) having an amino acid sequence expressed by the formula (X is H or H-Lys; Y is OH or Lys-OH). Selection from the ingredient (A) is then carried out to afford a polypeptide (B) having an amino acid sequence in which X is H and Y is Lys-OH in the formul. The resultant ingredient (B) is subsequently hydrolyzed with a carboxypeptidase B to afford a polypeptide having an amino acid sequence in which X is H and Y is OH in the formula. The ingredient (C) is then hydrolyzed with a vitamin K-dependent carboxylase to produce purified human OC without containing any other biological ingredients. A gene (plasmid pOC 980) capable of coding Glu-OC which is the ingredient (A), as necessary, is integrated into a vector to provide a recombinant DNA. The obtained recombinant DNA is then used to transform Escherichia coil and the resultant transformant strain is subsequently cultured to produce human OC which is a polypeptide.
709,286. Manicuring devices. JELLINCK, G. Aug. 9, 1951 [Sept. 1, 1950], No. 18761/51. Class 81(2) A nail coating comprises a series of layers, two or more layers being of waterproof, flexible and elastic material, which are attached to a support sheet by a watersoluble glue. The coating comprises a waterproof elastic layer 1 of optically reflecting material to which a glue layer 4 is applied, a transparent layer 2 which is coloured and may have metallic powder, glass pellets or mother-of-pearl varnish embedded therein and a protective transparent waterproof layer 3. The transparent layers 2, 3 may consist of synthetic resins. The film may be cut into nail-shaped patches of different sizes which are arranged in sets on a support. After soaking in water the patches are detachable from the support and may be applied to the nails, any excess film being trimmed off at the nail edge..The glue layer 4 is either supplied on the film or may be applied before the film is placed on the nail.
Cambodian Americans have high risk for major depressive disorder and for type 2 diabetes. Depression is a known risk factor for diabetes. Some antidepressants can also increase risk of diabetes by causing weight gain. DREAM will test the effect of lifestyle and medication therapy management (MTM) compared to social services (control) on diabetes risk among depressed Cambodian Americans. Community health workers (CHWs) will deliver the lifestyle intervention and assist pharmacists with MTM. Lifestyle and biological risk factors for diabetes, such as depressive symptoms, HbA1c and insulin sensitivity, will be measured before and after the interventions.
INTRODUCTION: Abdominal wall hernias are a frequent cause of abdominal pain-related emergency department visits. Our study aimed to establish the connection between lactate levels and patient outcomes in those with abdominal pain due to abdominal wall hernias.
MATERIALS AND METHODS: Our research followed a retrospective, observational, and descriptive approach and two center. We included patients who visited the emergency department for abdominal pain and were confirmed to have abdominal wall hernias through ultrasound.
RESULTS: We enrolled 493 patients meeting the criteria. Median age was 65 years, with 54% (n = 266) being male. Regarding outcomes, 40.5% (n = 200) were hospitalized, 27.7% (n = 137) underwent surgery, and 7.9% (n = 39) underwent bowel resection. Mortality rate during hernia-related hospital admission was 0.6% (n = 3). For hospitalized patients, there were significant differences in white blood cell count, neutrophil count and percentage, platelet count, lymphocyte count, and percentage (p < 0.05). Patients undergoing resection showed significant differences in neutrophil count, neutrophil percentage, lymphocyte count, and lymphocyte percentage (p < 0.05). Lactate levels were statistically significant in all patient groups requiring hospitalization, surgery, and resection (p < 0.05). Sensitivity and specificity of lactate test results indicated in patients undergoing bowel resection, lactate values ≥1.96 mmol/L had a specificity of 64%, sensitivity of 71%, and a negative predictive value of 96% (p < 0.05).
CONCLUSION: Low lactate levels in patients presenting to the emergency department with abdominal pain caused by abdominal wall hernias have a high negative predictive value for excluding strangulation and the need for bowel resection. Therefore, we recommend the use of lactate as an additional diagnostic tool in emergency department presentations related to abdominal wall hernias.
Individuals randomized to the iCOVER arm will be approached by a trained RA who will obtain assent and perform the iCOVER intervention. After completing the iCOVER protocol, the unblinded RA will leave, and a blinded outcome assessor will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
Adiposity rebound (AR) refers to the second rise of the body mass index (BMI) curve that usually occurs between six and eight years of age. AR timing has a significant impact on patients' health: early AR (EAR), usually before the age of five, is considered to be the earliest indicator of obesity and its related health conditions later in life. Many studies have evaluated factors that can be predictors of EAR, and identified low birth weight and gestational weight gain as novel predictors of EAR, highlighting the role of the intrauterine environment in the kinetics of adiposity. Furthermore, children with breastfeeding longer than 4 months have been found to be less likely to have an EAR, whereas children born to advanced-age mothers, high maternal BMI had a higher risk of having an EAR. Some differences were found in the timing of AR in boys and girls, with girls being more likely to have EAR. The aim of this review is to answer the following three questions: 1) Which are the prenatal and perinatal factors associated with increased risk of EAR? Is gender one of these? 2) Which are the outcomes of EAR in childhood and in adulthood? 3) Which measures can be taken in order to prevent premature AR?
Despite wide endorsement of a biopsychosocial framework for pain, social aspects of pain remain rarely addressed in the context of pain prevention and management. In this review, we aim to 1) examine the broad scope of social determinants and consequences of pain and their interactions across multiple levels of organization, and 2) provide a framework synthesizing existing concepts and potential areas for future work on social aspects of pain, drawing upon socioecological, intersectional, and life course approaches. Integrating interdisciplinary theory and evidence, we outline pathways through which multilevel social factors and pain may affect each other over time. We also provide a brief summary of intrapersonal aspects of pain, which are thought to operate at the interface between individuals and the social context. Progressing from micro- to macrolevel factors, we illustrate how social determinants of pain can directly or indirectly contribute to pain experiences, expression, risk, prognosis, and impact across populations. We consider 1) at the interpersonal level, the roles of social comparison, social relatedness, social support, social exclusion, empathy, and interpersonal conflict; 2) at the group or community level, the roles of intimacy groups, task groups, social categories, and loose associations; and 3) at the societal level, the roles of political, economic, and cultural systems, as well as their policies and practices. We present examples of multilevel consequences of pain across these levels and discuss opportunities to reduce the burden and inequities of pain by expanding multilevel social approaches in pain research and practice. PERSPECTIVE: Despite wide endorsement of a biopsychosocial framework for pain, social aspects of pain are often unclearly defined, hindering their use in pain prevention, management, and research. We summarize the scope of social aspects of pain and provide a framework synthesizing existing concepts and potential areas for future work.
PURPOSE:To obtain an antibody to a product of a cancer suppressing gene prohibitin utilizable for diagnosing cancer or tumor. CONSTITUTION:The antibody to a product of a cancer suppressing gene prohibitin is an amino acid sequence of a part presumed to have high antigenicity in an estimated structure related to a cancer suppressing gene prohibitin of mammary cancer. This is an antibody) obtained by using a combination of a peptide capable of coding Cys-Thr-Tyr-Leu-Pro-Ala-Gly-Gln-Ser-Val- Leu-Leu-Gln-Leu-Pro-Gln with a carrier protein as an antigen. The immunoglobulin class is IgG and its molecular weight is about 150000. The molecular extinction coefficient [E<1>% (1cm), (280nm)] is 1.40. The chain length of the peptide used as the antigen is short. Thereby, its synthesis is readily carried out. A desired antibody can be prepared by a well-known technique itself including the synthesis of this antigenic peptide.
FIELD: pharmaceutical products. SUBSTANCE: system contains single-layer pellet core and polymer film coating. Core includes therapeutically active agent and hydrophilic polymer. In another version of invention, double-layer pellet core contains active substance and hydrophilic polymer in its first layer and hydrophilic polymer in its second layer. System has at least one opening in a part of film coating which is in contact with core or active substance-containing core layer. System may also have one ore several openings in its part being in contact with the second layer. Coating consists of ammonium-methacrylate copolymer and hydrophilic polymer is hydroxypropylmethylcellulose. EFFECT: eliminated use chlorinated solvents. 34 cl, 9 dwg, 2 tbl, 6 ex
The subarachnoid hemorrhage (SAH) is a relatively severe disease whose prognosis is particularly related to the early onset of arterial vasospasm, maximum between the 5th and 14th day after SAH. Many obstacles make it difficult screening and monitoring of such complication. The challenge is to be able to demonstrate a reduction in regional cerebral blood flow before the onset of irreversible parenchymal sequelae, responsible for the majority of long-term morbidity among survivors. In clinical routine, screening vasospasm is achieved by Doppler intracranial arteries (DTC). However, its sensitivity is poor with regard to the middle and anterior cerebral arteries. The gold standard for diagnosis is cerebral arteriography. However, vasospasm in arteriography or trans-cranial Doppler does not prejudice the appearance of a delayed ischemic deficit.

A technique of MRI infusion -l'Arterial Spin Labeling-, non-invasive and non-irradiating, repeatable over time, appears promising in the field. This sequence allows for routine, generate perfusion maps relating to the entire brain volume
CLINICAL RELEVANCE: A method for determining 10-2 deployment in glaucoma with the goal of detecting additional visual field sensitivity for the purpose of functional monitoring is proposed.
BACKGROUND: To provide a pilot method for determining when to deploy the 10-2 visual field (VF) test grid in glaucoma by characterising the 'functional vulnerability zone'.
METHODS: The cross-sectional 24-2 (central 12 locations) and 10-2 VF results from 133 eyes of 133 glaucoma subjects were used to describe the central Hill of Vision using VF sensitivity. The 'volume' (defined using arbitrary units, A.U.) under the Hill was calculated. A greater A.U. on the 10-2 indicated a functional vulnerability zone (FVZ), signifying additional clinical dynamic range for potential future monitoring. The main outcome measures were calculated A.U. and 24-2 factors which were significantly related to A.U. differences between 24-2 and 10-2.
RESULTS: Over 55% of patients had an FVZ (A.U. greater using 10-2). Several 24-2 features (worse mean deviation, worse central 24-2 mean defect, and a higher proportion of defective locations) were significant in the FVZ cohort compared to non-FVZ. 24-2 mean deviation levels at which 10-2 may be favoured were low at -3.16 to -3.62 dB. Specifically, 5 or more defective central 24-2 test locations were associated with an FVZ. Subjects exhibiting a less severe defect on the 10-2 were more likely to have an FVZ, indicating its potential for future VF monitoring.
CONCLUSIONS: The authors propose several clinical markers, focussing on the 24-2, which can guide clinicians on when the 10-2 may have utility in glaucoma assessment. The authors provide a pilot reference spreadsheet for clinicians to visualise the likelihood of 10-2 utility in the context of an FVZ.
Disclosed is a small molecule dye for use in imaging in the near-infrared window, namely between 1000 nm-1700 nm wavelength. The present dyes are also useful for photoacoustic imaging and photothermal therapy. The dyes have a structure of a D-A-D (donor-acceptor-donor) fluorescent compound core and side chains rendering the compounds water soluble and easily conjugated to hydrophilic polymers and/or targeting ligands. Further disclosed is compound, CH1055 that can be PEGylated, conjugated to a targeting ligand, or conjugated to taurine. Key steps utilized to assemble the core structure of the target included a cross-Suzuki coupling reaction, iron reduction and N-thionylaniline induced ring closure. Four carboxylic acid groups were introduced into the donor-acceptor-donor (D-A-D) type fluorescent compound to impart a certain aqueous solubility and to allow facile conjugation to targeting ligands.
Each patient will be evaluated as both the experimental and control group. In line with the patient's aspiration needs, two different suction methods will be applied and the effects of the methods will be evaluated on the same patient. In the study, open suction applied to the patient will be considered as the control group, and closed suction will be considered as the experimental group. The first suction of the same patient during the day will be performed as open suction, and the second suction will be performed as closed suction. Pain and physiological parameters will be evaluated before, during and 30 minutes after each sucking session.
PURPOSE:To provide the titled promoting agent containing nucleic acid, nucleotide, nucleoside and/or nucleic acid base and vitamin C and/or its salt. CONSTITUTION:The objective agent for promoting the resortation of the hematopoietic organ contains (A) nucleic acid (e.g. originated from synthetic or natural source including DNA and RNA), nucleotide, nucleoside and/or nucleic acid base (originated from synthetic or natural source and having deoxyribose group or robossse group) and (B) vitamin C and/or its salt (originated from synthetic or natural source, having 100% or high purity; e.g. vegetable juice, natural juice of fruit such as orange, lemon, etc.). It can be used in the form of solid, fluid or liquid. Dose: 6-50g, preferably 10-40g daily in 1-3 divided doses. The agent is effective to promote the restoration of the strength of cancer patient, especially to promote the restoration of the hematopoietic function of the bone marrow.
Induction chemotherapy with FLAG starting on day 1 and venetoclax given on days 3-16. The G-CSF component of FLAG will continue until count recovery (ANC at least \> 1000). FLAG dosing will be standard and uniform for all patients and venetoclax dosing will be determined according to institutional guidelines based on the prophylactic antifungal therapy chosen for use during induction therapy. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
The invention discloses a hysteroscopic operation uterus expansion monitoring instrument and a using method thereof, relating to the technical field of medical appliances; comprises a central processing part, a sensor and a man-machine interaction part. The sensor collects the flow and pressure data of the uterus swelling medium inlet and outlet in real time in the hysteroscope operation and the weight of the leakage liquid, and transmits the data to the central processing part in real time. The central processing part converts the data obtained from the sensor into real-time absorption rate of the uterus swelling medium, absorption capacity of the uterus swelling medium, actual pressure in a uterine cavity and uterus swelling time, and then compares the real-time absorption rate with a preset safety range to alarm if the real-time absorption rate exceeds the preset safety range. The invention realizes real-time monitoring and danger forecasting of uterus expansion key indexes. The invention can accurately obtain the total uterus expanding time, can help clinical workers to effectively avoid serious complications of hysteroscopic surgery, and reduces the risk of the surgery. Meanwhile, hardware equipment guarantee is provided for medical researchers to carry out significant clinical research.
PROBLEM TO BE SOLVED: To obtain a polypeptide useful for e.g. preventing, diagnosing and treating adult diseases such as osteoporosis caused by active vitamin D3 level drop and having the activity of the subject enzyme catalyzing the final stage of vitamin D3 activation, and to obtain a gene encoding the above polypeptide. SOLUTION: This polypeptide has an amino acid sequence or the like of the formula, having 25-hydroxyvitamin D3 -1α-hydroxylase activity; and the other objective DNA encodes this polypeptide. The polypeptide of the present invention can be recombinantly produced from the DNA of the other present invention found in a cDNA library made from a mRNA prepared from the tissue of rats bred with a vitamin D3 -lacking feed (e.g. kidney). An active vitamin D3 can be formed by making the polypeptide of the present invention and 25-hydroxyvitamin D3 exist in an aqueous medium.
This is a randomized, double-blind, placebo-controlled, ascending single-dose study evaluating AMG 333 in healthy subjects and subjects with migraines. The study will consist of 8 cohorts: 7 cohorts of healthy subjects and 1 cohort of subjects with migraines. For cohorts 1 to 7, 8 subjects each will be enrolled, and subjects will be randomized such that 6 subjects will receive AMG 333 and 2 subjects will receive placebo (3:1 ratio). In cohort 8, up to 24 subjects with migraines will be enrolled, depending on enrollment rate and emerging safety and tolerability data. These migraine subjects will be randomized to receive AMG 333 or placebo in a crossover fashion. Both healthy and migraine subjects will be monitored in house for 4 days then allowed to return home for the remainder of the 14 day observation period. Both healthy and migraine subjects will keep headache diaries.
It is now generally believed that elderly may have slightly higher dietary protein requirements than those of the young-middle-aged adults. We have previously conducted related studies by the indicator amino acid oxidation (IAAO) technique, but more research data are needed to revise the protein requirements of the elderly. The main objective was to reevaluate the dietary protein requirements of healthy Chinese adults (65-80 years) without sarcopenia by using the IAAO technique. Nine healthy adult men and seven healthy adult women participated in the study, with protein intakes ranging from 0·1 to 1·8 g/(kg·d). Diets that delivered energy at a 1·5 resting energy expenditure were isocaloric. The amounts of phenylalanine and tyrosine needed to remain constant for each protein dosage. By applying a nonlinear mixed-effects model analysis on the F13CO2 data, which revealed a breakpoint in F13CO2 in response to graded protein intakes, the mean protein requirement was calculated. The mean estimated average requirement (EAR) for healthy elderly Chinese adults without sarcopenia was determined to be 0·94 g/(kg·d). The protein recommended nutrient intake (RNI) determined using various derivation approaches ranged from 1·13 to 1·36 g/(kg·d). The EAR for Chinese adults without sarcopenia aged 65-80 years in this study is 6·8 % higher than the current recommended EAR (0·88 g/(kg·d)). The RNI derived using various derivation approaches are all greater than the current RNI (0·98 g/(kg·d)). This trial was registered with the Chinese clinical trial registry as ChiCTR2200061382.